Evidence map›Paper›PMID 42666762›Full record

ArticleCureus2026

Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report.

Gabriel B Rashba, Lucas Kaplan, David Bolos, Armine Baltayan, Simon Backer

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gabriel B RashbaInternal Medicine, Olive View - UCLA Medical Center, Sylmar, USA.
Lucas KaplanHematology and Oncology, Olive View - UCLA Medical Center, Sylmar, USA.
David BolosHematology and Oncology, Olive View - UCLA Medical Center, Sylmar, USA.
Armine BaltayanPathology, Olive View - UCLA Medical Center, Sylmar, USA.
Simon BackerPathology, Olive View - UCLA Medical Center, Sylmar, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine carcinoma is a rare, biologically diverse malignancy that frequently presents with metastatic disease, which can carry a poor prognosis. Its symptomatology is often nonspecific, resulting in delayed diagnosis with substantial tumor burden. Platinum-based chemotherapy remains the cornerstone of treatment, although outcomes remain poor and novel therapeutic strategies are needed. We report a case of newly diagnosed metastatic neuroendocrine cancer in a patient presenting with vague constitutional and gastrointestinal symptoms, ultimately complicated by impending hepatic failure from extensive liver involvement. Initial evaluation raised greater concern for lymphoma or thyroid malignancy, given the pattern of lymphadenopathy and imaging findings. However, tissue biopsy ultimately revealed metastatic neuroendocrine carcinoma. This case underscores the aggressive nature of the poorly differentiated neuroendocrine carcinoma subtype, the importance of early recognition, and the challenges of managing patients with rapidly progressive disease.

Indexed as

benign thyroid nodulesetoposide and carboplatin combinationhepatomegalypalliative systemic therapyplatinum chemotherapypoorly differentiated neuroendocrine carcinoma

Identifiers

PMID42666762
PMCPMC13524009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.